HS-CSPC@EC2612A

Jade Pharmaceutical Group Discloses 2025 Annual Report with Revenue Growth

Sino-Pharm Group reports 24.5% profit decline in FY2025 and proposes dividend distribution

Sino-Pharm Group's Aripiprazole Injection Receives Drug Registration Approval

Sino-Pharm Obtains Approval for 32mg Aprepitant Injection for Post-Operative Nausea and Vomiting

Stone Pharmaceutical's SYH2082 Injection Approved by China NMPA and FDA for Clinical Trials

CSPC PHARMA to Release FY2025 Earnings on March 25 During-Market (BJT), Forecast Revenue HKD 31.05 B, EPS HKD 0.4834

Jade Pharmaceutical Completes Gene Editing Research on ATTR and Publishes Findings

Sage Pharmaceutical Innovation Revenue 21.58Bn, Net Loss 241Mn in 2025

Sino-Med's SYH2059 Inhalation Therapy Approved for Clinical Trials in China and the US

Stone Pharmaceutical Cell Valley Medical Technology Co., Ltd established

Stone Pharmaceutical's SYH2059 Inhalation Powder Approved for Clinical Trials by FDA

Jiayao Group's New Drug SYH2059 Receives FDA Approval for Clinical Trials in the U.S.

Stone Pharmaceutical Group's Indacaterol Mometasone Inhalation Powder Approved for Clinical Trials in China

Stone Pharmaceutical's Emicizumab Injection Receives Approval for Clinical Trials from NMPA

Stone Pharmaceutical Group's Injectable Paclitaxel Albumin Nanoparticle Receives FDA Clinical Trial Approval

Huatai Pacific 上调 Sino Pharm's 2027 and Beyond Revenue Forecast and Provided Target Price

Jinyao Group's Long-Acting Ropivacaine Injection Approved for Clinical Trials in China

Sino-Pharm Group's SYH2082 Approved for Clinical Trials

Nomura expects 20% revenue growth for Stone Pharmaceutical Group in Q4 2025 and 上调 profit forecast

New 纶威's Subsidiary Receives NMPA Approval for Clinical Trials of SYS6023

7ROAD

NEW VISION CO

IDT INT'L

SEM HLDGS

NET-A-GO TECH

KAISA GROUP

ARES ASIA

AOM INT'L

TRIO IND ELEC

LING YUI

01093

From October 1, 2025 to December 31, 2025, the company has repurchased 0 shares, representing 0% for HKD 0 million. With this, the company has completed the repurchase of 102,570,847 shares, representing 0.88% for HKD 525.36 million under the buyback announced on September 19, 2024.

marketscreener

CSPC PHARMA

Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024.

159837

159506

513120

159570

520500

520880

513700

159849

512290

516930

562050

159992

516500

513060

512010

159316

520690

CSPC Pharmaceutical Launches 2026 Share Award Scheme as 2018 Plan Nears Limit

Tip Ranks

E Fund CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

CSPC Pharmaceutical Launches 2026 Share Award Scheme as 2018 Plan Nears Limit

02800

09992

Hong Kong Stocks Extend Gains Wednesday; Pop Mart, CSPC Earnings Miss Estimates

TRACKER FUND

FL2 CSOP HSI

FI CSOP HSI

China Southern Hang Seng ETF

ChinaAMC Hang Seng ETF

CSOP HSI ETF

Hang Seng Index

ISHARESHSI

POP MART

FI2 CSOP HSI

Hong Kong Stocks Extend Gains Wednesday; Pop Mart, CSPC Earnings Miss Estimates

06808

00700

09988

01810

06869

Hong Kong stocks rose moderately during intraday trading, with the three major indices collectively in the green, and the Hang Seng TECH Index rising 0.67%. In terms of sectors, consumer retail performance diverged, with SUNART RETAIL up 3.18%. Meituan's 9.87% gain boosted market sentiment, while POP MART slumped over 20%. The market is focusing on the Federal Reserve's moves and economic data such as the Manufacturing PMI, maintaining an overall pattern of volatile consolidation

- As of March 25, Hong Kong stocks are moderately rising, with major indices showing gains; the Hang Seng Index is up 0.35% to 25,151.91, yet has not surpassed the March 20 peak.  
- Market sentiment remains cautious due to fluctuating local consumption and employment indicators, with investors monitoring key economic metrics and uncertainties from the Federal Reserve's policy direction.  
- Notable stocks include CSPC Pharmaceutical, rising 3.36% with a transaction volume of HKD 663 million, and Jiangxi Copper, increasing 4.35% with a volume of HKD 589 million.

Market Heartbeat

SUNART RETAIL

TENCENT

BABA-W

MEITUAN

XIAOMI-W

CNOOC

YOFC

BYD COMPANY

ZIJIN MINING

SMIC

JIANGXI COPPER

DONGFANG ELEC

GIGADEVICE

WANGUO GOLD GP

Hang Seng TECH Index

Meituan

HSTECH ETF

Hong Kong Stocks Intraday | Hang Seng Index Rises 0.35%, Retail Diverges, Meituan Rises 9.87%

CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates

CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates

CSPC Pharmaceutical Group (HK:1093) reported a revenue decline to RMB26.0 billion for 2025, with profits slipping to RMB3.88 billion. Despite this, the board raised the full-year dividend by 11.5% and continued share buy-backs, indicating confidence in cash flow. The company is navigating a transition in China's pharmaceutical sector towards innovation, with 76 new drugs approved. Analysts rate the stock as a Hold with a price target of HK$10.70. CSPC focuses on finished drugs and is positioned to benefit from China's emphasis on high-quality drug development.

CSPC Profit Slips but Dividend Rises as China Pharma Shifts to Innovation

300765

CSPC Pharmaceutical logs FY net income attributable RMB 3,882.1 mln

CSPC Innovation

CSPC Pharmaceutical logs FY net income attributable RMB 3,882.1 mln

CSPC PHARMA announced its 2025 annual performance, with revenue of RMB 26.006 billion, a year-on-year decrease of 10.4%. Shareholders' profit attributable to the company was RMB 3.882 billion, a year-on-year decrease of 10.3%; earnings per share were RMB 0.3398. A final dividend of HKD 0.15 was declared, compared to HKD 0.10 in the same period last year. The total annual dividend was HKD 0.29, an increase of 11.5% year-on-year. Basic profit was RMB 3.534 billion, a year-on-year decrease of 24.5%

AASTOCKS

"Blue Chip" CSPC PHARMA's annual net profit fell by 10.3%, final dividend increased to HKD 0.15

CSPC PHARMA 2025 revenue RMB 26.01 billion, estimate RMB 27.82 billion. 2025 net profit RMB 3.88 billion, estimate RMB 4.87 billion. Final dividend per share HKD 0.15

Wallstreetcn

CSPC PHARMA announced that its developed GLP-1/GIP receptor dual agonist peptide long-acting injection (SYH2082) has been approved by the National Medical Products Administration of China to conduct clinical trials in China. The approved clinical indication is for weight management in populations with obesity or overweight combined with at least one weight-related comorbidity

CSPC PHARMA SYH2082 injection has been approved to conduct clinical trials

CSPC Pharma Gets China Nod for Obesity Drug Trial

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

ICBCCS SSE STAR Biology and Medicine ETF

CSPC Pharma Gets China Nod for Obesity Drug Trial

01428

09626

06030

00016

On March 17th, Hong Kong stocks closed with mixed performance across the three major indices. The Hang Seng Index rose slightly by 0.13%, maintaining a range-bound consolidation. The retail and investment banking sectors performed strongly, with BRIGHT SMART surging 46.71% driven by increased liquidity. Tencent Holdings fell by 1.52%, topping the trading volume list, while the overall market was active but remained in a narrow fluctuation pattern

- On March 17, Hong Kong stocks displayed mixed performance, with the Hang Seng Index closing at 25,868.54 points, up 0.13%.  
- The retail sector showed strength, driven by recovering consumer demand, while the investment banking and brokerage sectors surged due to increased market liquidity.  
- Key stocks included Yao Cai Securities, which soared 46.71%, and Tencent, which fell 1.52%, amidst varying performances across sectors and overall market vigilance regarding macroeconomic factors.

BRIGHT SMART

BILIBILI-W

CITIC SEC

SHK PPT

Tencent Holdings Limited

Tencent

Hong Kong stocks close | Hang Seng Index slightly rises 0.13% maintaining consolidation, BRIGHT SMART surges 46.71% leading the way

Hot trading industry trends on August 7 and related Hong Kong semiconductor stocks. Hong Kong semiconductor stocks opened lower in early trading but then surged strongly, with Innoscience gaining over 11%, and industry leader SMIC rising over 3%. Core logic: On the news front, on August 1, Innoscience officially responded to rumors of collaboration with NVIDIA. The announcement stated that the company has recently partnered with global AI technology leader NVIDIA to jointly promote the large-scale implementation of the 800VDC (800-volt direct current) power architecture in AI data centers. Clear signals of a cyclical bottom: Global semiconductor inventory reduction is nearing its end...

NVIDIA

SMIC HK SDR 5to1

SJM HOLDINGS

MGM CHINA

FIT HON TENG

WUXI APPTEC

WuXi AppTec

INNOCARE

InnoCare Pharma

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

GALAXY ENT

Galaxy Entertainment Group

NAGACORP

WYNN MACAU

MELCO INT'L DEV

SANDS CHINA LTD

Sands China

INNOVENT BIO

COWELL

HUA HONG SEMI

Hua Hong

SHANGHAI FUDAN

FMSH

INNOSCIENCE

SOLOMON SYSTECH

TIGERMED

Tigermed

Apple

Hot Trades in Hong Kong Stocks (8.7)｜ Chip Stocks Rebound Strongly, Apple Supply Chain Follows; Xiaomi and Pharmaceuticals Retreat Under Pressure

Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's &#34;Stablecoin Ordinance&#34; will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.

HENGRUI PHARMA

Hengrui Pharma

3SBIO

OSL GROUP

CPIC

SUNSHINE INS

CR HOLDINGS

CHINA LIFE

China Life

SINO BIOPHARM

GUOTAI JUNAN I

AIA-R

AIA Group

Hot Trades in Hong Kong Stocks (7.28)｜Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday

HS-CSPC@EC2612A(25504.HK)

HS-CSPC@EC2612A Stock Performance Chart

Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024.

CSPC Pharmaceutical Launches 2026 Share Award Scheme as 2018 Plan Nears Limit

Hong Kong Stocks Extend Gains Wednesday; Pop Mart, CSPC Earnings Miss Estimates

Hong Kong Stocks Intraday | Hang Seng Index Rises 0.35%, Retail Diverges, Meituan Rises 9.87%

CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates